Skip to nav Skip to content

Clinical Trial Search

306 Clinical Trials Found

Clinical Trial 90035

Disease Site: Unknown Sites
PI: Vargas Madueno, Fernando

Clinical Trial 22078

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Disease Site: Brain and Nervous System
PI: Grogan, Patrick

Clinical Trial 22286

Disease Site: Leukemia, other
PI: Shah, Bijal

Clinical Trial 22380

A Phase II Multicenter, Open Label, Non-Randomized Study of Neoadjuvant and Adjuvant Treatment with IPH5201 and Durvalumab in Patients with Resectable, Early-Stage (II To IIIA) Non-Small Cell Lung CancEr (MATISSE)
Disease Site: Lung
PI: Chiappori, Alberto

Clinical Trial 22595

Disease Site: Multiple Myeloma
PI: Paba Prada, Claudia

Clinical Trial 23059

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
Disease Site: Myeloid and Monocytic Leukemia
PI: Sallman, David

Clinical Trial 23063

An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Disease Site: Breast
PI: Han, Heather

Clinical Trial 21626

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 21707

A Proof of Concept Study of TBio-4101 (an Autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) Using Short-Term Cultured, Selected Autologous TIL following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Solid Tumors (Phase 1)
Disease Site: Colon, Melanoma, skin, Rectum
PI: Sarnaik, Amod

Clinical Trial 21887

A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
Disease Site: Leukemia, other
PI: Padron, Eric

Clinical Trial 21997

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Disease Site: Other Skin
PI: Eroglu, Zeynep

Clinical Trial 22002

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach
PI: Kim, Dae Won